Horizon Therapeutics Public Limited's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Horizon Therapeutics Public Limited (HZNP) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Horizon Therapeutics Public Limited vs Its Competitors
- TTM: Trailing 12-month revenue of 3,643M vs 849,773M combined for tracked competitors (0.4% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+3.6% annualized vs trailing 12 months), vs decelerating (-24.9%) for its tracked peer group.
- Growth: Horizon Therapeutics Public Limited generated 7.7% revenue growth year over year in Q2 2023, vs -7.3% for its tracked competitors combined.
- Profitability: Its 13.5% net margin compares with 9.0% for the peer group.
- Peer revenue share: Horizon Therapeutics Public Limited accounted for 0.6% of combined revenue among its tracked peer group, up from 0.5% a year earlier.
- Peer differentiation: Revenue per employee of $2.80M compares with $0.91M for the peer group (3.1x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
HZNP Sales vs. its Competitors, Q2 2023
Horizon Therapeutics Public Limited reported revenue growth of 7.71 % year on year in Q2 2023, above its competitors' combined revenue change of -7.25 %.
With a net margin of 13.46 %, Horizon Therapeutics Public Limited achieved higher profitability than its competitors (8.95 %).
Horizon Therapeutics Public Limited generated 0.59 % of the combined sales of its peer group, up from 0.51 % a year earlier.
Horizon Therapeutics Public Limited vs. its Competitors, Q2 2023
Revenue growth, year on year
Net income growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Horizon Therapeutics Public Limited and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Horizon Therapeutics Public Limited Company | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (5) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Horizon Therapeutics Public Limited's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs 7.7% for Horizon Therapeutics Public Limited. Horizon Therapeutics Public Limited's share of combined industry revenue moved from 0.12% to 0.12%, a gain of 0.00 percentage points.
Horizon Therapeutics Public Limited's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Horizon Therapeutics Public Limited Company | Yes | No | No | No |
| Competitors combined (193) | ||||
| High-Confidence Competitors (5) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 62.50 % (5 of 8) | 0.00 % (0 of 8) | 28.60 % (2 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
HZNP Stock Performance relative to its Competitors
HZNP Stock Performance relative to High-Confidence Competitors
HZNP Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Ventyx Biosciences Inc | 282.9% | Outperformed |
| 2 | Spruce Biosciences Inc | 282.9% | Outperformed |
| 3 | Damora Therapeutics Inc | 282.9% | Outperformed |
| 4 | Anaptysbio Inc | 282.9% | Outperformed |
| 5 | 180 Life Sciences Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Horizon Therapeutics Public Limited's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Horizon Therapeutics Public Limited Company
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Horizon Therapeutics Public Limited Company | 27,190.33 | 3,643.45 |
| Akari Therapeutics Plc | 1,154,318.17 | - |
| Eli Lilly And Company | 1,058,703.83 | 79,665.80 |
| Johnson and Johnson | 652,897.56 | 97,929.00 |
| Beone Medicines Ltd | 549,863.54 | 6,128.24 |
| Abbvie Inc | 466,251.17 | 64,386.00 |
| SUBTOTAL | 6,432,455.19 | 883,395.04 |
Sign in to see all competitors of Horizon Therapeutics Public Limited Company.
Sources: Horizon Therapeutics Public Limited Company's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Horizon Therapeutics Public Limited Company versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Horizon Therapeutics Public Limited's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Zevra Therapeutics Inc | Named by the company | 85% |
| Spyre Therapeutics Inc | Named by the company | 85% |
| Centessa Pharmaceuticals Plc | Named by the company | 85% |
| Viridian Therapeutics Inc | Named by the company | 85% |
| Tradeup Acquisition Corp | Named by the company | 85% |
| Abbvie Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Horizon Therapeutics Public Limited's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Horizon Therapeutics Public Limited's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Johnson and Johnson | Oncology 29.26 % |
| Merck and Co Inc | Pharmaceutical segment 88.88 % |
| Amgen Inc | Reportable 100.00 % |
| Abbott Laboratories | Diabetes Care 17.78 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Horizon Therapeutics Public Limited Company.
Horizon Therapeutics Public Limited's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Horizon Therapeutics Public Limited Company | 27,190 | 2,802,652 | 336,925 |
| Akari Therapeutics Plc | 1,154,318 | - | -4,674,667 |
| Eli Lilly And Company | 1,058,704 | 1,593,316 | 534,224 |
| Johnson and Johnson | 652,898 | 695,518 | 149,411 |
| Beone Medicines Ltd | 549,864 | 510,686 | 54,642 |
| Abbvie Inc | 466,251 | 1,129,579 | 110,807 |
| PEERS TOTAL | 6,405,265 | 913,569 | 114,097 |
Sign in to see all peers for Horizon Therapeutics Public Limited Company.
Horizon Therapeutics Public Limited's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Horizon Therapeutics Public Limited Company | United States 97.76 % |
| Eli Lilly And Company | United States 61.21 % |
| Johnson and Johnson | United States 57.42 % |
| Beone Medicines Ltd | United States 51.69 % |
| Merck and Co Inc | EMEA 23.60 % |
| Gilead Sciences Inc | United States 70.78 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Sign in to see all peers for Horizon Therapeutics Public Limited Company.
Horizon Therapeutics Public Limited's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (342 companies). See the full Major Pharmaceutical Preparations industry profitability benchmarks.| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 75.23 % | 64.69 % (avg) | +10.5 pp |
| Operating Margin | 14.09 % | industry median | +168.0 pp |
| EBITDA Margin | 21.82 % | -7.31 % (avg) | +29.1 pp |
| Capital Intensity (Capex / Revenue) | 2.26 % | 4.92 % (avg) | -2.7 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Horizon Therapeutics Public Limited's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (342 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns. See the full Major Pharmaceutical Preparations industry valuation benchmarks.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 55.4x | 25.1x | +30.2x |
| EV / EBITDA | 30.6x | 17.3x | +13.3x |
| P/B | 4.7x | 4.5x | +0.2x |
| Return on Equity | 8.54 % | industry aggregate | -2.38 % |
| Return on Invested Capital | 4.01 % | -2.95 % (avg) | 6.96 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Horizon Therapeutics Public Limited's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 154.94 % | 29.60 % | 14.07 % | 19.78 % | -3.02 % | 69.26 % | 46.63 % | 12.48 % |
| Operating Margin | 7.31 % | -15.00 % | -35.45 % | 18.17 % | 9.74 % | 22.27 % | 16.83 % | 17.01 % |
| Return on Invested Capital | 1.60 % | -3.40 % | -9.26 % | 5.76 % | 2.57 % | 6.57 % | 4.62 % | 4.84 % |
| P/E | 330.5x | - | - | 71.9x | 16.3x | 46.8x | 45.9x | 44.6x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Horizon Therapeutics Public Limited's Strategic Group Map
Every company in Horizon Therapeutics Public Limited's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Horizon Therapeutics Public Limited is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Horizon Therapeutics Public Limited's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.26 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Horizon Therapeutics Public Limited's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Horizon Therapeutics Public Limited's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Horizon Therapeutics Public Limited's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Horizon Therapeutics Public Limited falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Horizon Therapeutics Public Limited's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 168.0 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+3.6% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
- A meaningful share of tracked competitors (43.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-24.9% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Horizon Therapeutics Public Limited's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Horizon Therapeutics Public Limited Company | 2.57 | 4.04 | 0.50 |
| Akari Therapeutics Plc | 0.23 | 0.26 | 0.04 |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Johnson and Johnson | 0.37 | 1.05 | 0.60 |
| Beone Medicines Ltd | 2.30 | 3.16 | 0.23 |
| Abbvie Inc | 0.16 | 0.75 | - |
Sign in to see all peers for Horizon Therapeutics Public Limited Company.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Horizon Therapeutics Public Limited's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Horizon Therapeutics Public Limited Company | Q2 2023 | +7.7 % | +108.4 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Johnson and Johnson | Q2 2026 | +6.6 % | -0.1 % |
| Beone Medicines Ltd | Q2 2026 | +29.7 % | +151.3 % |
| Abbvie Inc | Q2 2026 | +10.2 % | +284.3 % |
| PEERS TOTAL | +7.3 % | -8.6 % |
Sign in to see all peers for Horizon Therapeutics Public Limited Company.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Horizon Therapeutics Public Limited's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Horizon Therapeutics Public Limited Company | Q2 2023 | -4.9 % | +81.9 % |
| Akari Therapeutics Plc | Q1 2026 | - | - |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Johnson and Johnson | Q2 2026 | +5.5 % | +26.7 % |
| Beone Medicines Ltd | Q2 2026 | +6.4 % | -57.0 % |
| Abbvie Inc | Q2 2026 | -1.3 % | +19.7 % |
Sign in to see all peers for Horizon Therapeutics Public Limited Company.
Horizon Therapeutics Public Limited's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Horizon Therapeutics Public Limited Company | 4.81% | 5.71% | 8.54% |
| Akari Therapeutics Plc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Johnson and Johnson | 10.60% | 13.30% | 25.74% |
| Beone Medicines Ltd | 7.82% | 10.32% | 14.24% |
| Abbvie Inc | 4.68% | 9.11% | - |
Sign in to see all peers for Horizon Therapeutics Public Limited Company.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Horizon Therapeutics Public Limited's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Horizon Therapeutics Public Limited Company | 62.49 | 7.46 |
| Akari Therapeutics Plc | - | - |
| Eli Lilly And Company | 39.77 | 13.29 |
| Johnson and Johnson | 30.97 | 6.67 |
| Beone Medicines Ltd | 830.16 | 89.73 |
| Abbvie Inc | 74.37 | 7.24 |
| PEERS AVERAGE | 58.31 | 7.28 |
Sign in to see all peers for Horizon Therapeutics Public Limited Company.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.